cyrilzakka/clinical-trials huggingface dataset:
Effect of the Different Methods of Kinesiology Taping on the Muscle Contraction Performance of Fatigued Biceps Brachii

Recently, kinesiology tape is a common intervention in clinic and sport. According to the theory mentioned by the founder (Dr. Kenzo Kase), the elasticity of kinesiology tape has different effects from different taping skill. For muscle and fascia, taping could promote or inhibit contraction of muscle. For skeletal system, the intervention could correct posture and improve movement pattern through limiting joint mobility. For swelling, it may increase circulation of lymph during acute stage. However, whether these theories are feasible are still controversial in most studies.

The differences between results may be related to the high heterogeneity of taping method and outcome measures. On the other hand, there are lack of studies with high quality. The differences of taping method and skill should be considered for investigating the effect of kinesiology tape. And the performance of muscle contraction should be assessed by accurate instruments.

Double-blind and crossover study design will be used in this study. The taping method is divided into 4 types: Tradition (from origin to insertion), Cross, New (from insertion to origin) and Control (non-taping). The order of types will be assigned to subjects randomly. The 4 types of taping will be applied in 2 days that one week apart. Ultimate physical rehabilitation system (Pris RS, BTE, USA) will be used to access the differences of muscle strength and muscular endurance between different taping skills. The aims are to investigate the effect of the different method of kinesiology tape on performance of fatigued biceps brachii.

Eligibility Criteria:
Inclusion Criteria:

* healthy adults aged 20 years or older

Exclusion Criteria:

* Those who were unable to follow verbal instructions, had open wounds, or were allergic to kinesiology tape were excluded.
Clinical Trial on Harmonic Focus Shears Versus Ligasure Small Jaw and Clamp-and-tie Technique for Total Thyroidectomy

The Harmonic Focus and Ligasure small-Jaw are the last device designed for thyroid surgery. The aim is to assess: 1. decrease of operative time (minutes); 2. decrease of post-operative blood loss (milliliters); 3. decrease of post-operative stay (days); decrease of post-operative complications (%, hypocalcemia, laringeal nerve demage), compared to traditional dissection in a prospective randomized trial of total thyroidectomy procedures, for benign disease.

A single-blinded prospective randomized controlled trial was conducted at a tertiary referral center. A total of 120 patients who required a thyroidectomy for thyroid benign disease, will be randomized to either Harmonic Focus or Ligasure small-Jaw or clamp-and-tie technique during thyroidectomy. The operative time (minutes), morbidity rate (%), post-operative blood loss (milliliters), hospital stay (days), post-operative hypocalcemia (%), and cost of thyroidectomy (euros) were compared between the three groups.

Eligibility Criteria:
Inclusion Criteria:

* thyroid benign disease

Exclusion Criteria:

* malignant disease
* thyroid malign disease requiring lymphadenectomy
* coagulatory disease
Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament

In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones. For the multidrug-resistant tuberculosis (MDR-TB) patients, who are resistant to the major first-line anti-tuberculosis drugs such as Rifampin and Isoniazid, the second-line agents, like Cycloserine in this research, are in frequent use. Taking patients' safety into consideration, therapeutic drug monitoring of Cycloserine has been listed as a routine examination during the tuberculosis treatment and established a suggested Cycloserine serum concentration of 20\~35 mcg/mL.

While this suggested drug concentration was set up, it isn't suitable to all races in the world. The investigators plan to develop the therapeutic drug monitoring protocols and a suggested treating concentration fitting for Asian (Taiwanese). In addition, through this research, the investigators can also realize that factors causing different pharmacokinetics and the clinical outcomes in different Cycloserine level.

In all treatments of tuberculosis, the second-line drugs are usually less effective but have more drug toxicity than the first-line ones. For the multidrug-resistant tuberculosis (MDR-TB) patients, who are resistant to the major first-line anti-tuberculosis drugs such as Rifampin and Isoniazid, the second-line agents, like Cycloserine in this research, are in frequent use. Taking patients' safety into consideration, therapeutic drug monitoring of Cycloserine has been listed as a routine examination during the tuberculosis treatment and established a suggested Cycloserine serum concentration of 20\~35 mcg/mL.

While this suggested drug concentration was set up, it isn't suitable to all races in the world. The investigators plan to develop the therapeutic drug monitoring protocols and a suggested treating concentration fitting for Asian (Taiwanese). In addition, through this research, the investigators can also realize that factors causing different pharmacokinetics and the clinical outcomes in different Cycloserine level.

Eligibility Criteria:
Inclusion Criteria:

* 5 days and more of Cycloserine taking
* Asians

Exclusion Criteria:

* Cancer patients
* AIDS patients
* Combined AIDS-TB patients
* Pregnant subjects
* Anyone whose medical and medication records are unclear
A Smartphone App on Medication Adherence

This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Schizophrenia is a mental disorder that causes severe functional disabilities and imposes a heavy economic burden. Poor medication adherence is one of the major causes of relapse of psychiatric symptoms in schizophrenic patients. This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.

Eligibility Criteria:
Inclusion Criteria:

* schizophrenia
* aged 20 to 65 years
* able to read traditional Chinese
* owning a smartphone
* currently admitted at a psychiatric day-care center

Exclusion Criteria:

* Intellectually disabled or severe cognitive function impairment (Dementia)
Recreational Basketball to Increase Participation in Diabetes Prevention

The purpose of this study is to assess the efficacy of adapting the National Diabetes Prevention Program (NDPP) to include recreational sports in effort to increase physical activity (PA) and promote lifestyle changes that can help reduce the risk of developing Type 2 Diabetes Mellitus. The hypothesis is that both the traditional NDPP and the NDPP+ Basketball will be considered feasible. The primary outcome is to assess whether the intervention (NDPP+BB) compared to the standard of care (NDPP only) will result in greater weight loss, lower A1c, and increased engagement in physical activity.

The NDPP has successfully helped to reduce the rate of Type 2 Diabetes Mellitus (T2DM) through moderate weight loss and increased physical activity(PA). Kaiser Permanente Georgia (KPGA) members, identified as being at risk to develop type 2 diabetes will be recruited to participate in the intervention trial testing DPP vs. NDPP+ BB study arms. Participants will be randomized into 1 of 2 groups (traditional DPP curriculum or DPP + basketball).

The central objective of this project is to determine the feasibility of adapting the NDPP to include recreational basketball as an exercise component among KPGA population of overweight, pre-diabetic adults ages 18-44 using novel translational science approach and qualitative formative research tools. The secondary objective is to implement the adapted NDPP + BB program among a pre-diabetic KPGA adult members, 18-44 years living in Atlanta and determine post-program efficacy in achieving the desired 5 percent weight loss goal.

The objective is to contribute beneficial information to clinical and operational leaders across KP and beyond, as they consider approaches to improve overall participation rates in the NDPP, particularly for young and middle-aged adult members, leveraging interest in a popular recreational team-based sport such as BB. Longer-term, the goal is to reduce diabetes risk.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-44 years
* BMI \>= 25 kg/m2
* Previous diagnosis of prediabetes as defined:
* HbA1c 5.7 to 6.4% at baseline
* Not engaged in high exercise levels (self-report of less than 300 minutes of exercise per week)
* Not engaged in other lifestyle intervention program in past 2 years
* Ability to read in English and provide informed consent
* Ability to walk unassisted for 30 minutes
* Ability to jump in place

Exclusion Criteria:

* Diabetes due to underlying conditions
* Type 1 Diabetes
* Type 2 Diabetes
* End Stage Renal Disease (ESRD)
* Myocardial Infarction within the last 12 months
* Cancer treatment
* Congestive Heart Disease
* Not currently pregnant
* Any history of seizures or uncontrolled neurologic or psychiatric condition that may interfere with the intervention plan
Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

A placebo controlled study of the impact on insulin sensitivity and lipid profile of maraviroc 300 mg twice daily in HIV negative male volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must have documented negative HIV serology by ELISA and P24 antigen
* Subjects must be clinically well males aged between 18 to 60 years.
* Fasting blood glucose, total cholesterol and triglycerides within normal limits
* Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)
* Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥ 50,000/mm3; hemoglobin ≥ 8.0 g/dL)
* Serum amylase ≤ 1.5 × ULN
* Sexually active males must use condoms during the course of the study
* Life expectancy ≥ 1 year
* Willing and able to provide informed consent

Exclusion Criteria:

* Subjects with a waist hip ratio \> 0.97 or BMI \> 28 kg/m2 will be excluded
* Acute or chronic hepatitis B infection (determined by positive hepatitis B surface antigen result at the screening visit)
* Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody result at the screening visit)
* Other metabolic syndrome or disease process in the opinion of the investigator likely to cause marked disturbance in glucose and lipid homeostasis including hypertension.
* Receiving on-going therapy with any of the following:

  * Metabolically active medications
  * Any lipid-lowering medication
  * Hormonal agents (oestrogens or androgens)
  * Glucocorticoids
  * Beta-blockers
  * Thiazide diuretics
  * Thyroid preparations
  * Psychotropic agents
  * Anabolic steroids
  * Megestrol acetate
A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.

To compare the effect of Crinone 8% administered once daily versus other vaginal progesterone in terms of ongoing pregnancy rate 5 weeks after embryo transfer as well as patient convenience.


Eligibility Criteria:
Inclusion Criteria:

* 18-40 years
* Regular menstrual cyclus 25-35 days
* both ovaries present
* No more than 2 previous IVF attempts
* Have given written informed consent

Exclusion Criteria:

* More than 2 previous attempts
* Known drug abuse
* Known allergies to the study medication
* No embryo transfer performed in the study cycle
* Previous participating in the study
Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension

This study will evaluate the efficacy and safety of weak extremely low frequency electromagnetic fields (ELF-EMF) in mild and moderate essential hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Ages: 20 years to 74 years
* Genders : Both
* The severity of hypertension: mild and moderate (WHO/ISH criteria stage I-II) Systolic blood pressure (SBP) \>/= 140 and/or diastolic blood pressure (DBP)\>/= 90 (untreated hypertension cases)

Exclusion Criteria:

* Any of the following medical conditions:
* Severe essential hypertension (DBP \>110)
* Secondary or malignant hypertension
* History or symptoms of cerebral vascular disease
* History of myocardial infarction
* History of angina pectoris, atrial fibrillation, heart failure and arrhythmia
* Renal dysfunction (serum creatinine \> 2.1mg/dl)
* Severe hepatic dysfunction
* Uncontrolled diabetes
* Allergy, drug sensitivity or chronic skin disease
* Peptic ulcer disease
* Current pregnancy or lactation
* Depression that needs to be treated
* Hypertension controlled with antihypertensive medication
Effects of Microgravity on Central Aortic Pressure During Parabolic Flights

Cardiovascular events remain the main cause of death of the industrialized world (Global status report on noncommunicable diseases 2010. Geneva, World Health Organization, 2011). Arterial hypertension, hyperlipoproteinemia, smoking, diabetes and family history represent the main cardiovascular risk factors. Arteriosclerosis leads to coronary heart disease, cerebrovascular insufficiency and peripheral vascular diseases that reflect in myocardial infarction and stroke.

The main objective of this experiment is to investigate the differential effect of microgravity on central aortic blood pressure.

The main criterion is the central aortic pressure (measured in mmHg). The hypothesis is that microgravity leads to an increased central aortic pressure.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers (men or women)
* Aged from 18 to 65
* Affiliated to a Social Security system and, for non-French resident, holding a European Health Insurance Card (EHIC)
* Who accepted to take part in the study
* Who have given their written stated consent
* Who has passed a medical examination similar to a standard aviation medical examination for private pilot aptitude (JAR FCL3 Class 2 medical examination). There will be no additional test performed for subject selection.

Subjects will be staff member of the team or of other teams participating in the parabolic flight campaign.

Exclusion Criteria:

* Person who took part in a previous biomedical research protocol, of which exclusion period is not terminated
* Treated or non-treated arterial hypertension
* History of cardiovascular disease
* Pregnant women
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple-dose study of orally administered VX-809 and VX-770 in healthy subjects. This study will evaluate safety and tolerability of VX-809 and VX-770 alone and in combination.

Subjects will be randomized to receive study drug or placebo during three 14-day treatment periods separated by 14-day washout periods. In Treatment Period 1, subjects randomized to study drug will receive VX-809 every 24 hours. In Treatment Period 2, subjects randomized to study drug will receive VX-770 every 12 hours. In Treatment Period 3, subjects will receive VX-809 every 24 hours and VX-770 every 12 hours. Subjects randomized to placebo will receive placebo during all treatment periods.

Enrollment is planned at 1 clinical site (Lenexa, Kansas). Up to 72 subjects will be enrolled. The study will be separated into 3 dose escalation cohorts. Cohort 1 and Cohort 2 will enroll 24 subjects. Cohort 3 is optional and may be conducted after a review of safety and pharmacokinetic data by Vertex.

Eligibility Criteria:
Inclusion Criteria:

* Male or female subject between 18 and 55 years of age, inclusive
* Body mass index (BMI) between 18.5 and 30.0 kg/m2, inclusive
* Subjects of child bearing potential and who are sexually active must meet the contraception requirements
* Female subject must have a negative serum pregnancy test at screening and Day -1

Exclusion Criteria:

* History of any illness that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject
* Participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever is longer) before the Screening visit
* Subject who has received VX-770 or VX-809 in a previous clinical study
Cementless Alumina-Alumina Total Hip and Hybrid

Evaluate the safety and efficacy of the CeramTec Acetabular Alumina Insert and CeramTec Alumina head when used with the Foundation Porous Coated Acetabular Shell and an Encore hip stem.


Eligibility Criteria:
Inclusion Criteria:

* Patients with inflammatory tissue disorders (e.g. rheumatoid arthritis, lupus, etc), osteoarthritis, post-traumatic arthritis or secondary arthritis, or avascular necrosis.
* Less than 70 on preoperative HHS score
* Primary total hip replacement
* Patient is likely to be available for evaluation for the duration of the study.

Exclusion Criteria:

* Patients with physical conditions that would eliminate adequate implant support or prevent the use of an appropriately sized implant (e.g., tumor)
* Previous surgery that has adversely affected bone stock (such as some hip pinning or some osteotomies) or prior total hip replacement.
* Insufficient quality or quantity of bone resulting from conditions such as:

  * Cancer, where radiation has destroyed the available bonestock
  * Congenital dislocation
  * Metabolic bone disease of the upper femur or pelvis
  * Femoral osteotomy revision
  * Girdlestone revision
  * Active infection of the hip joint
  * Old or remote infection
  * Other conditions that lead to inadequate skeletal fixation
* Neurological conditions that might hinder patient's ability to follow study procedures, e.g., to restrict physical activities (e.g., Severe Parkinson's, CVA on affected side)
* Patient's mental condition that may interfere with his ability to give an informed consent or willingness to fulfill the required follow-up of the study

  * Mental illness
  * Senility
  * Drug Abuse
  * Alcoholism
* Conditions that place excessive demands on the implant

  * Charcot's joints
  * Muscle deficiencies
  * Multiple joint disabilities
  * Refusal to modify postoperative physical activities
  * Skeletal immaturity
  * Obesity (50% over recorded body weight mass index)
* Greater than or equal to 70 on preoperative HHS score
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer

This protocol is intended to provide access to bemarituzumab (FPA144 an investigational agent) to a single patient with recurrent bladder cancer who had a response to study drug on FPA144-001. That study is closing and this expanded access protocol allows this single patient to continue receiving this agent.

Eligibility Criteria:
Inclusion Criteria:

1. Understand and sign an Institutional Review Board-approved informed consent form prior to receiving bemarituzumab
2. Previously enrolled on the FPA144-001 study, received bemarituzumab and obtained clinical benefit from the investigational product (IP) administration

Exclusion Criteria:

1. Pregnancy and lactation
Predictive Factors of Morbidity and Mortality and Overall Survival of Patients With Gastric Cancer : a Case Series

This is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the IBN ROCHD University Hospital Center in Casablanca. Evaluation from a series of 80 cases of gastric adenocarcinomas, follow-up to determine the prognostic factors influencing mortality, morbidity and survival.


Eligibility Criteria:
Inclusion Criteria:

* patients with gastric cancer

Exclusion Criteria:

* patients with benign tumors or other pathologies requiring gastric resection
Dominant Non-Dominant Upper Extremity in Gender

There are strength and functional differences between non-dominant and dominant extremities. This is important in the hand and extremity rehabilitation process. This situation also differs between genders. Comparison of the dominant and non-dominant limb can provide important clinical or rehabilitation field-related information. It is reported in the literature that manual dexterity, grip strength and joint position sense may differ between extremities. However, the relationship between this situation and the difference between genders has not been explained. It is thought that examining this difference can be extremely useful in determining achievable goals in hand rehabilitation and in customizing care for different groups.

Many treatment protocols compare the strength of the injured extremity to the uninjured extremity or compare it to normative data from the same group of individuals. There is controversy about the difference in grip strength between dominant and non-dominant hands in left- and right-hand dominant individuals. There is no study in the literature that evaluates the differences in muscle strength, joint position sense and upper extremity function skills between dominant and non-dominant upper extremities between genders. It is very important to include bilateral activity training in rehabilitation programs that aim to improve upper extremity mobility and speed. In addition, it will contribute to the accurate evaluation of activity and participation limitations, the determination of priorities, the selection of the right activity in task-specific and target-oriented treatment approaches, and the achievement of more effective results when integrated with technology-supported approaches. Therefore, the aim of our study is to fill this gap in the literature by comparing the differences between dominant and non-dominant upper extremities between genders.

Eligibility Criteria:
Inclusion Criteria:

1. Being between the ages of 18-25
2. Volunteering to participate in the study

Exclusion Criteria:

1. Having trauma (fracture, dislocation) in the last year
2. Doing sports or activities that require bilateral activity (playing music, knitting, sports, etc.)
3. Being diagnosed with any neurological or orthopedic disease that will affect hand-eye coordination
4. Having had upper extremity surgery
5. Having any Botox injection in the last 6 months
6. Those who did not agree to participate in the study